Figure 1.

(A) Changes in HBV DNA from baseline over time in the finotonlimab and sorafenib groups. A declining trend in HBV DNA levels was observed in the finotonlimab group compared to the sorafenib group. (B) Kaplan–Meier curve shows the TTD of HBV DNA in patients with HCC who received finotonlimab or sorafenib. The median TTD in the finotonlimab group was significantly longer than that in the sorafenib group (18.8 months vs. 5.6 months). (C) Changes in HBV DNA levels over time in patients with OS above the median OS (blue line) vs. below the median OS (brown line) in the finotonlimab group. Patients with longer OS (greater than the median OS) consistently had lower HBV DNA levels compared to those with shorter OS (less than the median OS). (D) The diagram of the mutual effects of HBV suppression and anticancer effects. DNA: Deoxyribonucleic acid; GT: Greater than; HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; HR: Hazard ratio; LE: Less than or equal to; NE: Not evaluable; OS: Overall survival; TTD: Time to deterioration.